Abstract

The ability to predict the extent of passive intestinal drug absorption is very important for efficient lead candidate selection and development. Physicochemical-based absorption predictive models previously developed use solubility, partition coefficient and p K a as drug input parameters for intestinal absorption. Alternatively, this study looks at the relationship between melting point and passive transport for poorly soluble drugs. It is based entirely on the expression derived from the General Solubility Equation (GSE) that relates melting point to the product of intrinsic solubility and partition coefficient. Given that the melting point of a compound is one of the first and more reliable physical properties measured, it can be advantageously used as a guide in early drug discovery and development. This paper elucidates the interesting relationship between the melting point and dose to the fraction absorbed of poorly soluble drugs, i.e., class II and IV compounds in the Biopharmaceutics Classification System. The newly defined melting point based absorption potential (MPbAP) parameter is successful at distinguishing 90% of the 91 drugs considered being well absorbed (FA > 0.5) or poorly absorbed. In general, lower melting compounds are more likely to be well absorbed than higher melting compounds for any given dose. The fraction absorbed for drugs with high melting temperatures is limited by the dose to a greater degree than it is for low melting compounds.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.